| Prev Close | 143.38 |
| Day Low/High | 131.35 / 144.77 |
| 52 Wk Low/High | 119.01 / 497.49 |
Moderna, Inc. (MRNA)
136.25
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 397.76B |
| Market Cap | 57.03B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Beijing's Covid Outbreak Sends Chinese Stocks South
The CSI 300 plunged to its lowest level in two years as residents of the Chinese capital stripped grocery store shelves bare amid lockdown fears.
The Market Is Flipping Elon Musk the Bird
Also, play the companies that benefit from inflation, not Cathie's clowns, which are hurt by it.
Relief Rally, Charting the Indexes, Fed Talk, Taiwan Semi, Musk Bids for Twitter
The market roared, but the pros did not tag along in size. They either have to catch up, or they are just not coming.
Looking for a Pairs Trade? Go Long China, Short Europe
Here's why China is winning.
Need to Know Tear Sheet... for Next Week
Multi-Day Conferences - Goldman Sachs Chemical Intensity Days Conference - Keybanc Virtual Healthcare Conference - DA Davidson (Inaugural) EV & Energy Transition Virtual Conference - Wolfe Research Software Conference - Piper Sandler 22nd Annual En...
Could Fresh Global Outbreaks Move the Needle for Moderna?
As several parts of the world struggle with Covid-19 surges, MRNA could win in the long war against the pandemic.
Blue Monday, Technical Damage, Death Cross, FOMC, China, Raskin, Lockheed Martin
The Nasdaq Composite suffered a 'death cross' back in mid-February and what happened after that is now clear to see.
Markets Ablaze, Ukraine Invasion, Neon Nightmare, What If? Gold and Silver
Thought the semiconductor shortage had already been severe? That's where the cards currently lie.
Big Premarket Movers
To the upside: - +94% (to be acquired by Apollo Funds for $20.00/shr in cash valued at $7.1B) - +20% (strength attributed to report received take over interest) - +15% (earnings, guidance) - +14% (earnings) - +10% (earnings) - +8.6% (earnings) - +7....
You Don't Know Who Is Swimming Naked Until the Tide Goes Out
* The Dunning- Kruger Effect is vividly seen these days in the business media and elsewhere * Avoid the self confident and smug talking heads Business commentators, strategists, analysts, money managers and "talking heads" have short memories - but...
Is Moderna's Bumpy Ride Lower Over for Now?
The stock is trading higher Monday on full approval for its Covid vaccine.
When the Pandemic Becomes an Endemic, Here's How the Economy Benefits
It would be a rare positive in a market that has more of its share of concerns for investors at the moment.
Buy Moderna? A Subscriber Wants to Know
Let's take a look at the charts and indicators.
Omicron Threat, Slowing Economic Activity, Week Ahead, 4 Trading Thoughts
Bear in mind that as Omicron threatens to, and will to some degree, slow economic activity, the real catalyst will be the political and policy response.
Eye on Skyworks, a Potential Acquisition and Omicron
Looks like we are going to open the last day of what has been a miserable week for the markets in the red, based on where futures are currently trading. Small-caps, once again, look like they will take the brunt of the early decline. Skyworks Soluti...
Sorry, but Price Is Not Truth
* I have little conviction in this afternoon's violent rally "Nothing like price to change sentiment." - The Divine Ms. M. I read the same people you follow on Twitter. I listen to the same people you watch on Fin TV. They are emboldened (and bu...
Bitten Market, Waning Volume, Virus Thoughts, Jobless Claims Quirk, CPI Watch
Plus, a quick look at earnings report winners and losers from Thursday after the market closed.
Let's Check Up on 2 Immunology-Focused Oncology ETFs
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
As 2021 IPO Names Tumble, These 2022 Debuts Are Still Drawing Excitement
Despite the expectation of a tougher sledding for high-flying IPOs, optimism remains for a few key names.
The Surge, Tech Plays, Trading Marvell and MongoDB, Debt Ceiling, Taxes, Omicron
Plus, One must ask themselves... Are Russia and China satisfied with making Ukraine and Taiwan uncomfortable? Do they understand the costs?
Omicron Panic, Scared Money, A Tech Bright Spot, Fed Talk, My After-Hours Trades
Whether panicked sales over these past few days, especially Wednesday, prove to be either the 'fast' or 'smart' money remains to be seen.
Should Investors Believe in Bounces as Markets Get Choppy?
Sector selection will remain paramount as pandemic effects continue to permeate.
Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
Omicron Uncertainty Is Causing Fresh Selling
The challenge for traders is determining how long the Omicron uncertainty will weigh on the markets.
Why I Am Now Less Bearish
* While I am not bullish, I am less bearish * On a (tactical) trading and even on an investing basis, markets may have overreacted to the Omicron news on Friday * I covered a bunch of shorts on Friday * It might be time to consider being a bit more ...
Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler
I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.
